Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Net Income towards Common Stockholders data on file, last reported at $25.4 million in Q2 2026.

• Quarterly Net Income towards Common Stockholders rose 42.62% year-over-year to $25.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $80.7 million (up 1583.88% YoY) and the FY2025 annual result came in at $59.0 million, up 236.61% from the prior year.
• Net Income towards Common Stockholders advanced to $25.4 million in Q2 2026, from $22.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $224.1 million in Q3 2022 to a low of -$49.2 million in Q4 2023.
• A 5-year average of $15.0 million and a median of $2.3 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 833.67% — and 2023, when it tumbled 155.63%.
• Tracing KNSA's Net Income towards Common Stockholders over 5 years: stood at $88.5 million in 2022, then slumped by 155.63% to -$49.2 million in 2023, then jumped by 81.95% to -$8.9 million in 2024, then soared by 259.75% to $14.2 million in 2025, then surged by 79.11% to $25.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $25.4 million (Q2 2026), $22.6 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.